NEW: Eli Lilly and Company's weight-loss drug Zepbound improved breathing problems in highly-anticipated studies that may convince more insurers to cover the $1,000-a-month treatment. More here: bloomberg.com/news/articles/…

Hello! Not to spoil the shock but the news is that I'm leaving STAT after eight wonderful years and will soon be covering some very large drug companies with the team Bloomberg News.

Some reporters (Deena Shanker) get chocolate, others get … GLP-1 protein powder

Did you even watch the eclipse if you don’t spiral about having eye damage after

I AM FINE

This is a massive loss for the city of Chicago

New from me for Businessweek Bloomberg & Bloomberg Economics: On Good Friday the Milwaukee factory that's churned out the locks that secure America's high school lockers for 85 yrs is closing. And that's emblematic of a swing-state soft spot in Biden's factory renaissance.
bloomberg.com/graphics/2024-…

Here is an early look at the front page of a special section wrapping today's Wall Street Journal on.wsj.com/3vyw07m

Spoke with ⁦Apple News⁩ Today about our reporting on how the fentanyl crisis is taking center stage as the 2024 presidential election nears.

Tune in, here: apple.news/nowPlaying/Azk…

Exclusive: Bernie Sanders wants to discuss lowering the price of Ozempic with Novo Nordisk's top executive as soon as next week.

With Robert Langreth for Bloomberg:
bloomberg.com/news/articles/…

Read-a-Thon to Mark One Year Since Evan Gershkovich’s Detainment wsj.com/world/read-a-t… via The Wall Street Journal

Ozempic could be profitably produced for less than $5 a month even as maker Novo Nordisk charges almost $1,000 in the US, according to a study trib.al/LlcQyXh

People across the US are struggling to get their hands on the powerful new obesity drug Zepbound, even as the FDA and Eli Lilly deny there's a shortage trib.al/MmNWKkx

NEW: People across the US are struggling to get their hands on the powerful new obesity drug Zepbound, even as the FDA and Eli Lilly say it's not in shortage.

More from me, Ike Swetlitz & Jemima Denham here: bloomberg.com/news/articles/…

To understand the 2024 US presidential election, it is essential to understand the politics of fentanyl.

With more than 270K deaths from synthetic opioids since just before the Covid pandemic, no corner of this country has gone unscathed.

A thread...🧵
bloomberg.com/news/features/…

Jared Whitlock Over at Bloomberg, Madison Muller, Michelle Fay Cortez + Sangmi Cha had a great scoop on Lilly's reliance on WuXi for the active base ingredient for Mounjaro and Zepbound:

bloomberg.com/news/articles/…

'You're on a tight timeline, you’ve got cash running out, and you’ve got to get into the clinic, and all of a sudden they can't manufacture your Phase I material... that’s going to be bad'

What happens if the US forces biopharma to cut ties with WuXi: endpts.com/wuxi-became-a-…

1/ Even though Rite Aid's bankrupt, its CEO is making $300,000 a month. Its lawyers are making $2,000 an hour. Lenders are making millions. But thousands of opioid victims who have sued the company are expected to get nothing at all. Gift link --> bloomberg.com/news/features/…